Credit Suisse Ag Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Credit Suisse Ag

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$543.48 - $670.97 $2.5 Million - $3.09 Million	-4,600 Reduced 46.94%	5,200 $3.28 Million
Q3 2021 Nov 12, 2021	BUY	$574.03 - $680.96 $3.62 Million - $4.29 Million	6,300 Added 180.0%	9,800 $5.93 Million
Q2 2021 Aug 16, 2021	SELL	$472.8 - $558.54 $1.61 Million - $1.9 Million	-3,400 Reduced 49.28%	3,500 $1.96 Million
Q1 2021 May 14, 2021	SELL	$446.73 - $548.2 $6.08 Million - $7.46 Million	-13,600 Reduced 66.34%	6,900 $3.27 Million
Q3 2020 Nov 13, 2020	SELL	$544.75 - $658.21 $16.3 Million - $19.7 Million	-29,900 Reduced 59.33%	20,500 $11.5 Million
Q2 2020 Aug 12, 2020	BUY	$493.32 - $643.92 $9.87 Million - $12.9 Million	20,000 Added 65.79%	50,400 $31.4 Million
Q1 2020 May 13, 2020	SELL	$336.18 - $494.43 $5.61 Million - $8.26 Million	-16,700 Reduced 35.46%	30,400 $14.8 Million
Q3 2019 Nov 12, 2019	SELL	$273.46 - $318.39 $5.33 Million - $6.21 Million	-19,500 Reduced 29.28%	47,100 $13.1 Million
Q2 2019 Aug 14, 2019	BUY	$299.6 - $414.82 $16.9 Million - $23.4 Million	56,300 Added 546.6%	66,600 $20.8 Million
Q1 2019 May 14, 2019	BUY	$372.08 - $439.57 $3.83 Million - $4.53 Million	10,300 New	10,300 $4.23 Million

1,529

84.1M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.1B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.